{"id":"nifurzide","rwe":[],"tags":[{"label":"nifurzide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A07AX04","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ricridene","offLabel":[],"synonyms":["nifurzide","ricridene"],"timeline":[],"approvals":[],"brandName":"Ricridene","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nifurzide","explanation":"Imagine your body's cells are like tiny factories, using energy to function properly. Bacteria, on the other hand, have their own way of making energy. Nifurzide works by blocking the bacteria's energy-making machinery, ultimately killing the bacteria and helping to treat infections.","oneSentence":"Nifurzide is thought to work by inhibiting bacterial enzymes, disrupting the bacterial cell's ability to produce energy.","technicalDetail":"Nifurzide is believed to exert its antibacterial effects by inhibiting the bacterial enzyme dihydroorotate dehydrogenase, which is essential for the synthesis of pyrimidine nucleotides."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1931","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NIFURZIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:05:56.351413","biosimilars":[],"competitors":[],"genericName":"nifurzide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005282","UNII":"Z35R6K4C26","CHEBI":"CHEBI:135428","INN_ID":"4127","RXNORM":"31786","UMLSCUI":"C0068746","ChEMBL_ID":"CHEMBL2106530","KEGG_DRUG":"D07251","DRUGBANK_ID":"DB13325","PUBCHEM_CID":"9571044","IUPHAR_LIGAND_ID":"12365","MESH_SUPPLEMENTAL_RECORD_UI":"C029924"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":11,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"A07AX04","allCodes":["A07AX04"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ricridene (Nifurzide) is a small molecule drug in the nifurzide class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to understand its clinical applications and safety profile. As a result, its commercial status and generic availability are also unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}